Belgium-based Ablynx pens development deal with China's Eddingpharm
- Ablynx is selling the development rights of its rheumatoid arthritis (RA) medication ozoralizumab to Eddingpharm so that the company may register and commercialize the product in Greater China.
- Ozoralizumab is a next-generation TNF-alpha targeting ‘nanobody.’
- Ablynx will receive an upfront fee of $2.63 million, followed by payments for meeting commercial milestones and royalties up to 20%.
The activity around the Chinese pharmaceutical market is becoming increasingly intense. According to Ablynx CEO Edwin Moses, China is a "huge and developing market."
Eddingpharm is well positioned to develop Ablynx’s product, not only because of its development expertise in China, but also thanks to its expertise in nanobody-based development and inflammatory diseases.
- Pharma Times Ablynx signs RA deal with China’s Eddingpharm